Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis
- PMID: 38282393
- DOI: 10.1002/rmv.2508
Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis
Abstract
On 23 July 2022, the World Health Organization declared the global mpox outbreak as a public health emergency of international significance. The mpox virus (MPXV) that caused the outbreak was classified as clade IIb, which belongs to the West African clade. However, the relationship between MPXV clades and symptoms, as well as the severity of mpox outcomes, is not fully understood. Thus, we aimed to investigate the global mpox prevalence and the differences in clinical manifestations and outcomes among patients with mpox between pre-outbreak (2003-2021) and the current mpox outbreak. In this systematic review and meta-analysis, PubMed/MEDLINE, Web of Science, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were searched using the keyword "monkeypox" and "mpox" up to 13 October 2022. A random effects model was used to obtain the pooled prevalence and 95% confidence intervals. This study included 27 articles, and 5698 patients with mpox with 19 distinctive features from 19 countries across five continents were assessed. Patients with mpox during the 2022 mpox outbreak showed mild clinical manifestations and outcomes compared with those before the 2022 mpox outbreak: mild rash (relative ratio [RR]: 5.09, 95% confidence interval [CI]: 1.52-17.08), fever (0.68, 0.49-0.94), pruritus (0.25, 0.19-0.32), myalgia (0.50, 0.31-0.81), headache (0.56, 0.35-0.88), skin ulcer (0.32, 0.17-0.59), abdominal symptom (0.29, 0.20-0.42), pharyngitis (0.32, 0.18-0.58), nausea or vomiting (0.15, 0.02-0.93), conjunctivitis (0.11, 0.03-0.38), concomitant infection with HIV (1.70, 0.95-3 0.04), and death (0.02, 0.001-0.31). MPXV clade IIb exhibited higher infectivity but may cause mild disease symptoms and low mortality rate. It is important to consider MPXV infection in patients with mpox-related features and/or a history of sexual transmission to prevent the spread of the disease and recognise the current pandemic threat.
Keywords: 2003-2021; 2022; clinical feature; comparison; mpox; outbreak; prevalence; symptom.
© 2024 John Wiley & Sons Ltd.
Similar articles
-
Clinical manifestations of human Mpox infection: A systematic review and meta-analysis.Rev Med Virol. 2023 Jul;33(4):e2446. doi: 10.1002/rmv.2446. Epub 2023 Apr 13. Rev Med Virol. 2023. PMID: 37056203
-
Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review.JAMA. 2024 Nov 19;332(19):1652-1662. doi: 10.1001/jama.2024.21091. JAMA. 2024. PMID: 39401235 Review.
-
Therapeutics for treating mpox in humans.Cochrane Database Syst Rev. 2023 Mar 14;3(3):CD015769. doi: 10.1002/14651858.CD015769. Cochrane Database Syst Rev. 2023. PMID: 36916727 Free PMC article.
-
Epidemiology and phylogenomic characterisation of two distinct mpox outbreaks in Kinshasa, DR Congo, involving a new subclade Ia lineage: a retrospective, observational study.Lancet. 2025 Jul 5;406(10498):63-75. doi: 10.1016/S0140-6736(25)00294-6. Lancet. 2025. PMID: 40617661
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
Cited by
-
The resurgence of monkeypox clade Ib: a global health emergency and concern.Arch Virol. 2025 Mar 21;170(4):84. doi: 10.1007/s00705-025-06270-0. Arch Virol. 2025. PMID: 40116967 Review.
-
Review: Known, Emerging, and Remerging Pharyngitis Pathogens.J Infect Dis. 2024 Oct 23;230(Supplement_3):S173-S181. doi: 10.1093/infdis/jiae391. J Infect Dis. 2024. PMID: 39441194 Free PMC article. Review.
-
Characterization of Human Immortalized Keratinocyte Cells Infected by Monkeypox Virus.Viruses. 2024 Jul 26;16(8):1206. doi: 10.3390/v16081206. Viruses. 2024. PMID: 39205180 Free PMC article.
-
Health insurance status and severe mpox disease outcomes among sexual minority men in NYC: a retrospective cohort study.BMC Med. 2025 Jul 9;23(1):418. doi: 10.1186/s12916-025-04252-2. BMC Med. 2025. PMID: 40629412 Free PMC article.
-
Association of HIV infection and hospitalization among mpox cases: a systematic review and meta-analysis.BMC Infect Dis. 2025 Jan 22;25(1):102. doi: 10.1186/s12879-025-10512-6. BMC Infect Dis. 2025. PMID: 39844097 Free PMC article.
References
REFERENCES
-
- York A. The bodily distribution of monkeypox virus. Nat Rev Microbiol. 2022;20(12):703. https://doi.org/10.1038/s41579-022-00813-x
-
- Park S, Yon H. Global, regional, and national incidence and mortality of human monkeypox infection in 107 countries and territories, October 2022: a systematic analysis for World Health Organization database and rapid review. Life Cycle. 2022;2:e16. https://doi.org/10.54724/lc.2022.e16
-
- Yon H. Demographic, transmission, and clinical characteristics associated with human monkeypox infection, October 2022: a systematic analysis for World Health Organization database and brief review. Life Cycle. 2022;2:e17. https://doi.org/10.54724/lc.2022.e17
-
- Del Rio C, Malani PN. Update on the monkeypox outbreak. JAMA. 2022;328(10):921-922. https://doi.org/10.1001/jama.2022.14857
-
- Kang Y, Ahmad S. The emerging epidemics in recent: mpox. Life Cycle. 2023;3:e3. https://doi.org/10.54724/lc.2023.e3
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical